Where America's biggest companies are heading next.
We read what S&P 500 companies disclose and decode it into what matters: the strategic moves they are likely to make next, and the map of who they buy from, sell to and compete with.
Strategy radar
The highest-conviction calls from our latest research.
Keep share repurchases as the main use of excess cash through FY27, likely executing additional programs under the $5.0 billion authorization.
Cardinal HealthRead the analysisLean on Specialty and Care Services, rather than Pharmacy Benefit Services, as the main Evernorth profit engine through the 2027-2028 rebate-free transition.
CignaRead the analysisClose the American Oncology Network merger and fold it, with OneOncology, into a single community-oncology MSO business inside the new specialty-focused structure.
CencoraRead the analysisA heavier, internationally tilted build-out in fiscal 2027, with openings and capital spending at multi-year highs.
CostcoRead the analysisPay for the AI buildout with outside capital and pause buybacks, instead of funding it from free cash flow
Meta PlatformsRead the analysisKeep funding the AI infrastructure build with a larger share of debt, with further bond issuance in the coming year rather than a pullback in capital spending.
MicrosoftRead the analysisLatest research
Fresh analyses, published every weekday.






Most-referenced companies
How often other companies' disclosures name them as a customer, supplier, partner or competitor.
Read every analysis as it lands
Founding members get full strategy and relationship analysis on every covered company, the early signals behind each call, and a daily research email.
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.